MyCelx Technologies (AIM:MYXR) has seen its shares bubble up after a successful US trial of its water treatment technology.
The trial, at an industrial site in Newburgh, New York, showed its remediation system could reduce contamination from man made toxic chemicals - perfluoroakyl and polyfluoroalkyl compounds (PFAS) - to an undetectable level.
The company estimates the annual PFAS remediation cost in the US to be in excess of US$8bn.
Chief executive Connie Mixon said: "This test result is an important step forward in progressing towards our first commercial contract for PFAS remediation in the United States."
The company's shares are up 12.95% at 78.5p.
2.33pm: Ten Lifestyle boosted by UK wealth management deal
Ten Lifestyle Group (AIM:TENG) has continued its winning run of new business this year with a new contract with one of the UK's largest wealth managers.
The company operates a global concierge platform for the world's wealthy assisting them to organise and book travel, dining and live entertainment.
The new contract will see Ten initially launch its services in spring 2022, making concierge and lifestyle services available to a segment of the client's wealth management customers in the UK.
It has also agreed a number of other deals. These include a multi-year contract with existing client St. James's Place, renewing an existing large contract with a major UK private bank and having its digitally-enabled concierge services added to Barclays' Travel Plus Pack product.
Chief executive Alex Cheatle said: "[This new contract] is a significant development for Ten in the UK, our most mature market."
Ten's shares are up 4.11% at 116.08p.
12.20p: IQE says results will be in line with November's reduced guidance
IQE PLC (AIM:IQE) saw its shares slump in November after warning that weakening demand for smartphones would hit its sales.
But the latest update from the firm, which supplies semiconductor wafer products and advanced material solutions, has had a more positive effect, given there appears to be no more bad news.
It said full year revenues were expected to be in line with November's guidance of around £164mln at constant currency, subject to an external audit review.
New chief executive Americo Lemos said: “Having joined the business in January I am pleased we have delivered revenues in line with our November 2021 trading update. I have been very impressed by the calibre and commitment of the colleagues I have met during my first weeks with IQE as well as the quality of our world-leading innovation. I am very excited about the potential growth associated with macro technology trends and IQE’s position at the heart of these future products.”
Its shares - which dropped from more than 50p to 38p after the November warning - are up 7.18% today to 31.35p.
10.56am: Caspian Sunrise climbs after positive drilling update
Shares in Caspian Sunrise PLC (AIM:CASP) are shining after a positive drilling update.
The Kazakhstan-based company said initial production from Deep Well A8 on the Airshagyl structure at its flagship BNG Contract Area had been 120 barrels of oil per day for several days.
It said work continued to establish the full potential of the well.
Chairman Clive Carver said "The early results from Deep Well A8 are encouraging. With international oil prices in excess of $85 per barrel the Company is set for a good year."
Caspian has climbed 6.67% or 0.25p to 4p.
10.23am: Yü Group shrugs off energy industry woes to see revenues surge
With consumers facing soaring costs and suppliers going bust, it's safe to say the energy industry is in a volatile state.
But Yü Group PLC (AIM:YU.) has sparked up after saying full year profits would significantly beat market expectations.
The supplier of gas, electricity and water to the UK SME and corporate business sector said it had seen record quarterly bookings in the final three months of the year despite the problems facing the sector.
So full year revenues are expected to be up 50% to more than £150mln, driven by continued organic growth and the integration of Ampower
It said there was strong order visibility for 2022, with £156.5mln of contracted revenue, up from £93mln for 2021.
Its shares are up 11.71% to 310p.
9.24am: N4 Pharma boosted by link-up with government-funded innovation centres
N4 Pharma PLC (AIM:N4P) is looking healthy after an update on Nuvec, its delivery system for cancer treatments and vaccines.
After positive results on its effectivenes in inhibiting tumour growth, the company has begun work on further studies with the government-funded Medicines Discovery Catapult.
The company said the costs of all current and planned work would come from existing resources, and it remained well funded for 2022.
Chief executive Nigel Theobald said: "The oncology, gene therapy and protein replacement markets are very large and attracting significant and varied interest. Based on our current data, these markets provide the company with the quickest route to bring products into clinical trials, far quicker than using it for vaccines. With our vaccine work now continuing through Material Transfer Agreements, our primary focus is on these studies with Catapult and advancing our data set to a meaningful inflexion point in the coming months."
N4 is up 8.07% at 3.35p.
8.56am: Staffline (AIM:STAF) sees profits ahead of market expectations
Staffline (AIM:STAF) is in demand after a positive trading update.
The recruitment group said full year revenues were expected to rise 1.6% to £942.7mln after a strong second half.
Operating profit is forecast to more than double from £4.8mln to around £10mln, some 11% ahead of market expectations despite the pandemic and the widespread labour shortages.
It withdrew from a number of lower margin contracts, but gained new customers and further business from existing clients.
On the down side, its PeoplePlus business was restructed in 2020 but the discovery of incomplete records relatin to 2019 mean it will have to repay £2mln of revenues.
As for the the outlook, it said; "[The] momentum is expected to continue into 2022, supported by a strong new business pipeline, a lower overhead cost base and the expected post-COVID-19 recovery of historically strong Staffline (AIM:STAF) recruitment sectors, such as automotive, manufacturing, aerospace and travel. The board remains confident in the growth prospects for the Group in the medium-to-long-term."
Its shares have jumped 11.71% or 6.5p to 62p.
Also heading higher is Learning Technologies Group PLC (AIM:LTG).
The digital learning and talent management business said full year revenues were expected to jump from £132.3mln to £254mln.
Adjusted earnings are forecast to climb from £40.3mln to at least £53.7mln, driven by organic growth as well as contributions from acquisitions completed in the first half of 2021, Reflektive, PDT Global and Bridge.
The purchase of GP Strategies was completed last October, andit has seen a swifter than expected improvement in operational performance.
The company has climbed 6.33% to 157.8p.